Article

A systematic review and meta-analysis of Anakinra, Sarilumab, Siltuximab and Tocilizumab for Covid-19

2020-04-26

Abstract excerpt

<h4>ABSTRACT</h4> <h4>Background</h4> There is accumulating evidence for an overly activated immune response in severe Covid-19, with several studies exploring the therapeutic role of immunomodulation. Through systematic review and meta-analysis, we assess the effectiveness of specific interleukin inhibitors for the treatment of Covid-19. <h4>Methods</h4> Electronic databases were searched on 7 th January 2021 to...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 96f74c59-6533-50aa-ac46-3a00b3b33c66
DOI: 10.1101/2020.04.23.20076612

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

A systematic review and meta-analysis of Anakinra, Sarilumab, Siltuximab and Tocilizumab for Covid-19DOI 10.1101/2020.04.23.20076612Read

Tocilizumab versus sarilumab among adults hospitalised with COVID-19: target trial emulation across England and ScotlandSemantic proximity Read

Tocilizumab for patients with COVID-19 pneumonia. The TOCIVID-19 prospective phase 2 trialSemantic proximity Read

Tocilizumab, netakimab, and baricitinib in patients with mild-to-moderate COVID-19: a retrospective cohort studySemantic proximity Read

Tocilizumab treatment leads to early resolution of lymphopenia and myeloid dysregulation in patients hospitalized with COVID-19Semantic proximity Read

Course of inflammation and infection markers differ in ICU patients with severe COVID-19 under casirivimab- and/or tocilizumab application: an observational studySemantic proximity Read

Making sense of non-randomized comparative treatment studies in times of Covid-19: A case study of tocilizumabSemantic proximity Read

Risk of severe COVID-19 outcomes associated with immune-mediated inflammatory diseases and immune modifying therapies: a nationwide cohort study in the OpenSAFELY platformSemantic proximity Read

Tocilizumab Efficacy Across Inflammatory Subphenotypes in COVID-19-Related Acute Respiratory Distress Syndrome.Semantic proximity Read

COVID-19–Associated Macrophage Activation Syndrome: Clinical Characteristics, Treatment Patterns, and Outcomes from a Hospitalized CohortSemantic proximity Read

Timely Administration of Tocilizumab Improves Survival of Hospitalized COVID-19 PatientsSemantic proximity Read

Single Versus Multiple Doses of Tocilizumab in Critically Ill Patients with Coronavirus Disease 2019 (COVID-19): A Two-center, Retrospective Cohort StudySemantic proximity Read

Impact of FCGR2A rs1801274 and IL-6R rs2228145 polymorphisms on tocilizumab response in the Iranian population with severe COVID-19.Semantic proximity Read